Cargando…
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
BACKGROUND: Treatment resistant depression (TRD) affects 10–30% of patients with major depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs. placebo when both were initiated in addition to a new selective serotonin or serotonin norepinephrine reuptake inhibitor. Howe...
Autores principales: | Oliveira-Maia, Albino J., Morrens, Joachim, Rive, Benoit, Godinov, Yordan, Cabrieto, Jedelyn, Perualila, Nolen, Barbreau, Sebastien, Mulhern-Haughey, Siobhán |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669153/ https://www.ncbi.nlm.nih.gov/pubmed/38025433 http://dx.doi.org/10.3389/fpsyt.2023.1250980 |
Ejemplares similares
-
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
por: Oliveira-Maia, Albino J., et al.
Publicado: (2023) -
Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial
por: Young, A.H., et al.
Publicado: (2023) -
Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
por: Reif, A., et al.
Publicado: (2023) -
Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis
por: Döme, Péter, et al.
Publicado: (2021) -
Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)